Bristol Myers Squibb Q2 FY25: where the revenue came from and where it went
The whole income statement of Bristol Myers Squibb for this quarter, as one diagram: what earned the revenue, and what it went on.
- Period
- Apr 1 – Jun 30, 2025
- Reported
- Jul 31, 2025
Revenue$12.27B
+1% year over year
Gross profit$8.90B
73% margin
Operating profit−$0.46B
−4% margin
Net profit$1.31B
11% margin
Net profit is larger than what operations earned, because the statement adds $2.23B below it, under Other income, net.
The numbers
| Item | Value | Share of revenue | Year over year |
|---|---|---|---|
| Revenue | 12.27 | 100% | +1% |
| Growth portfolio | 6.60 | 53% | |
| Eliquis | 3.68 | 30% | |
| Revlimid | 0.84 | 7% | |
| Pomalyst/Imnovid | 0.71 | 6% | |
| Other legacy products | 0.22 | 2% | |
| Sprycel | 0.12 | 1% | |
| Abraxane | 0.11 | 1% | |
| Cost of revenue | −3.37 | 27% | |
| Gross profit | 8.90 | 73% margin | −1pp |
| R&D | −2.58 | 21% | −3pp |
| SG&A | −1.71 | 14% | −2pp |
| Other | −5.07 | 41% | +0pp |
| Operating profit | −0.46 | −4% margin | +0pp |
| Other income, net | 2.23 | ||
| Tax | −0.46 | ||
| Net profit | 1.31 | 11% margin | −3pp |
220 of 418 companies, most recently reported first
New results in your inbox
When a big company reports, we send you a link to its diagram before anyone has time to comment on it. This is a mailing list, not an account: it does not open the diagrams by itself. No spam, one-click unsubscribe.
Drag or use the arrow keys to see the rest